Award
National Institute on Aging 5R01AG078457-02
The Alzheimer's Disease Tau Platform Clinical Trial
Recipient
Not specified
Award Amount
$29,813,375.00
Ceiling
$29,813,375.00
Awarded
August 28, 2024
Identifier
5R01AG078457-02
A Phase 2 clinical trial award for testing tau-directed therapies in Alzheimer's Disease, emphasizing safety and biomarker validation.
Description
This project involves a Phase 2 platform trial testing tau-directed therapies for Alzheimer's Disease, focusing on safety, tolerability, and biological proof of concept using tau PET imaging and other biomarkers.